Excitement is mounting at Richmond Pharmacology as we approach the QTc workshop to be held on 29th September 2004 at St George's Hospital Medical School. The workshop has received much interest and is expected to be a huge success.Richmond Pharmacology has invited main representatives from the top pharmaceutical companies to attend a workshop where world-leading experts in cardiology from St George's Hospital Medical School and also the Medicines and Healthcare Products Regulatory Authority (MHRA) will speak on a range of QTc topics.Studies focussing on the QT interval have become of increased importance recently. A number of drugs have been withdrawn from the market as a result of their capacity to cause potentially fatal arrhythmias associated with the prolongation of the QT interval. Factors influencing the QT interval, regulatory aspects of drug induced QT interval prolongation, correcting or controlling the QT interval, and the definitive QT study will all be discussed, among other topics, at the workshop hosted by Richmond Pharmacology.To find more information on Richmond Pharmacology's QTc capabilities, or for further information on the QTc workshop, follow the link to our QTc studies page.It is not too late to register, please see the workshop page for further information. The QTc Studies page provides up to date information on the services offered by RPL in this area of expertise.

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event